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Abstract The rabbit polyclonal antibody against rat organic
anion transporting polypeptide 2 (oatp2) was raised and
immunoaffinity-purified. Western blot analysis for oatp2 de-
tected two bands (V74 and 76 kDa) in rat brain and a single
band (76 kDa) in the liver. By immunohistochemical analysis, the
oatp2 immunoreactivity was specifically high at the basolateral
membrane of rat hepatocytes. Functionally, the oatp2-expressing
oocytes were found to transport dehydroepiandrosterone sulfate,
N1 opioid receptor agonist [D-Pen2,D-Pen5]enkephalin, Leu-
enkephalin, and biotin significantly, as well as the substrates
previously reported. These data reveal the exact distribution of
the rat oatp2 at the protein level in the liver, and that oatp2
appears to be involved in the multispecificity of the uptaking
substrates in the liver and brain.
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1. Introduction
Recently, we and another group have independently iso-
lated a cDNA for Na-independent organic anion transport-
ing polypeptide 2 (oatp2) from rat retina [1] and brain [2].
Oocytes injected with the oatp2 cRNA showed taurocholate,
thyroxine (T4), triiodothyronine (T3) and conjugated steroid
(estradiol 17L-glucuronide and estrone sulfate) uptake in a
saturable manner [1,2]. Northern blot analysis and in situ
hybridization revealed that the oatp2 mRNA was highly ex-
pressed in the brain and liver [1], whereas NoeŁ et al. detected
an additional band in the kidney [2]. Although this discrep-
ancy may be attributed to the speci¢city of the probes, no
study has been made on the distribution of oatp2 at the pro-
tein level.
In this report, to identify the expression of oatp2 at the
protein level, Western blot and immunohistochemical analyses
of oatp2 were performed. The oatp2 immunoreactivity was
high in the liver, particularly at the basolateral membrane
of the hepatocytes. In contrast, no oatp2 immunoreactivity
was detected in the kidney, con¢rming our previous report
on the oatp2 mRNA distribution. The detailed pharmacolog-
ical characterization of oatp2 was also examined in Xenopus
laevis oocytes in order to identify the additional substrates for
oatp2.
2. Materials and methods
2.1. Preparation of rabbit antibodies for rat oatp2
A peptide containing 12 amino acids (CTEVLRSKVTED, position
650^661) at the carboxy-terminus of rat oatp2, a region that is di¡er-
ent from both rat oatp1 and oatp3, was synthesized [1]. This peptide
was linked to the maleimide-activated keyhole limpet hemocyanin
(KHL; Pierce). The KHL-linked peptide (1 mg/injection) was emulsi-
¢ed by mixing with an equal volume of the Freund’s adjuvant and
injected into female rabbits. Boosts were performed at 2, 6, and
8 weeks, and animals were killed at 10 weeks. The antibodies were
a⁄nity-puri¢ed using CNBr-activated Sepharose CL-4B (Amersham
Pharmacia Biotech) coupled with synthetic peptides according to the
standard procedure [3].
2.2. Preparation of liver membranes
Male Sprague-Dawley rats (200 g) were anesthetized and the liver
was resected. The liver was homogenized in a bu¡er containing 0.23 M
sucrose, 5 mM Tris-HCl pH 7.5, 2 mM EDTA, 0.1 mM phenylmeth-
ylsulfonyl £uoride, 1 Wg/ml leupeptin, and 1 Wg/ml pepstatin A. The
homogenate was centrifuged at 3000Ug for 15 min and the super-
natant was further centrifuged at 100 000Ug for 30 min. The resultant
pellet is referred to as the crude membrane fraction and was resus-
pended in a bu¡er of 0.23 M sucrose, 5 mM Tris-HCl, pH 7.5, and
2 mM EDTA [4].
2.3. Western blot analysis
Western blot analysis was performed by a modi¢cation of a pre-
viously reported method [3]. Brie£y, 10 Wg of crude membranes were
solubilized by a sample bu¡er (2% SDS, 125 mM Tris-HCl, pH 7.4,
20% glycerol, 2% 2-mercaptoethanol) at room temperature for 5 min
and applied onto a 10% SDS-polyacrylamide gel. After electrophore-
sis, proteins were transferred to polyvinylidene di£uoride membranes
(Bio-Rad). The blots were blocked with 5% non-fat dry milk in phos-
phate bu¡ered saline (PBS)-T (80 mM Na2HPO4, 20 mM NaH2PO4,
100 mM NaCl, pH 7.5, containing 0.1% Tween 20) overnight at 4‡C
and incubated with the a⁄nity-puri¢ed anti-oatp2 antibody (1 Wg/ml)
for 1 h at room temperature. The blots were then incubated with anti-
rabbit IgG conjugated with horseradish peroxidase (HRP, 1:5000
dilution, Amersham Pharmacia Biotech) for 1 h at room temperature.
Enhanced chemiluminescence kit was used for detection (Amersham
Pharmacia Biotech). To identify the antibody speci¢city, the anti-
oatp2 antibody was incubated with 10 Wg of the immunogen peptide
before use.
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2.4. Immunocytochemistry
Immunohistochemical analysis was performed as previously re-
ported [5]. Adult Wistar rats weighing 250^300 g were perfused trans-
cardially with 0.9% saline followed by 4% paraformaldehyde in 0.1 M
phosphate bu¡er under ether anesthesia. The specimens were im-
mersed in 30% sucrose/0.1 M phosphate bu¡er. Sections were cut at
a thickness of 20 Wm with a cryostat and mounted onto gelatin-coated
slide glasses. After incubation in PBS containing 0.05% Triton X-100,
the sections were incubated in 0.3% H2O2/methanol for the inhibition
of the endogenous peroxidase activities. The sections were then ex-
posed to 5% normal goat serum for 30 min to block non-speci¢c
staining. Subsequently, the sections were incubated with the primary
antibody at a ¢nal concentration of 1 Wg/ml, followed by incubation
with biotinylated goat anti-rabbit IgG (Vector Laboratories) for 1 h,
washed 6 times with PBS, and placed in the avidin-biotin-HRP com-
plex (ABC kit, Vector Laboratories). The sections were then washed
3 times with PBS and treated with 0.01% 3P,3-diaminobenzidine
tetrahydrochloride, Tris-HCl pH 7.5 and 0.002% H2O2. In control
experiment, sections were incubated with the primary antibody pre-
absorbed with 10 Wg/ml antigen peptide.
2.5. Expression of rat oatp2 in Xenopus oocytes
The cDNA encoding rat oatp2 was linearized and the capped
cRNA was transcribed in vitro with T7 RNA polymerase (Strata-
gene). Xenopus laevis oocytes were prepared as described previously
[1]. After an overnight incubation at 18‡C, healthy defolliculated oo-
cytes were microinjected with 10 ng of rat oatp2 cRNA and subse-
quently cultured for 48^72 h in a modi¢ed Barth’s medium (88 mM
NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM CaNO3, 0.41 mM
CaCl2, 0.82 mM MgSO4, 15 mM HEPES pH 7.6). Uptake of radio-
labeled chemicals was measured in a medium containing 100 mM
choline chloride, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES pH 7.5. Water-injected oocytes were used as controls. Five to
nine oocytes were prewashed in the uptake medium and incubated at
room temperature in 100 Wl of the same medium containing radio-
labeled substrate at the indicated concentration for 1 h. Uptake was
terminated by addition of 1 ml of ice-cold uptake bu¡er and the
oocytes were washed 3 times with 3 ml of ice-cold uptake bu¡er.
Each oocyte was dissolved in 500 Wl of 10% SDS and 4 ml of scintil-
lation £uid (Packard), and the oocyte-associated radioactivity was
counted in a Packard Tri-Carb 2100 liquid scintillation counter (Pack-
ard). The statistical signi¢cance was tested by unpaired t-test.
3. Results and discussion
3.1. Western blot analysis
Western blot analysis was performed after 10% SDS-poly-
acrylamide gel electrophoresis of the crude membranes (10
Wg). As shown in Fig. 1, the anti-oatp2 antibody recognized
a faint band in the brain (V76 kDa) and a closely spaced
doublet of proteins in the liver, with an apparent molecular
size of V74 kDa and V76 kDa. These oatp2-positive bands
disappeared completely when the antibody was preabsorbed
with the antigen peptide (data not shown), suggesting the
speci¢city of the detected bands. On the other hand, no im-
munoreactivity was detected in the kidney. These data are
consistent with our Northern blot analysis [1], and also sup-
port that oatp2 is not expressed in the kidney as much as
reported by NoeŁ et al. [2]. In the liver, the oatp2 antibody
detected two bands (Fig. 1); one is located at the same size as
that in the brain and the other is relatively low (detected by
the short exposure, data not shown). Because the predicted
apparent molecular size of rat oatp2 is 73.2 kDa [1,2] and
there are six putative glycosylation sites in its structure, the
existence of two bands may represent di¡erent manners of
glycosylation between the brain and liver.
In our experiment, oatp2 immunoreactivity was clearly de-
tected using 10 Wg of crude membrane (Fig. 1). On the other
hand, Western blot analysis detected faint oatp1 immunoreac-
tivity (V80 kDa) when the crude membrane of the liver (20
Wg) was used [6]. Comparing these data, it is suggested that, in
the liver, oatp2 is expressed more highly than oatp1 at the
protein level.
3.2. Localization of oatp2 in rat liver
By immunohistochemical analysis, the oatp2 immunoreac-
tivity was signi¢cantly detected around the central vein in the
liver (Fig. 2a). At high magni¢cation, oatp2 immunoreactivity
was observed at the basolateral (sinusoidal) membrane of the
hepatocyte that faces the sinusoid (Fig. 2b, indicated by ar-
rowhead). In contrast, no signal was detected intracellularly
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Fig. 1. Western immunoblot of rat oatp2. Western blot analyses of
rat liver membranes were performed with the a⁄nity-puri¢ed anti-
body against rat oatp2. 10 Wg of membrane was separated on 10%
SDS-PAGE gel under denaturing conditions and subjected to immu-
noblotting with the a⁄nity-puri¢ed antibody.
Fig. 2. Immunohistochemical localization of oatp2 in rat liver. a: Note that oatp2 immunoreactivity was seen in the liver around the central
vein (CV). b: At a higher magni¢cation, immunoreactivity was observed in the basolateral membranes of the hepatocytes (arrowhead). Magni¢-
cation view of the liver, 750U (a), 150U (b). Scale bar, 50 Wm (a) and 10 Wm (b).
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or at the canalicular membrane. This immunoreactivity was
speci¢c to oatp2, because preabsorption of the antibody with
excess peptide immunogen resulted in the complete abolition
of the immunostaining described above (data not shown). In
the liver, oatp1, another member of the oatps, is expressed at
the basolateral membrane of the hepatocyte [6]. GLUT-2 im-
munoreactivity is also distributed predominantly in the peri-
portal and the perivenous zones of the hepatocytes [7]. It is,
thus, suggested that oatp2 would be involved in the clearance
mechanisms at the basolateral membrane of hepatocytes, tak-
ing up its speci¢c substrates from the circulation (see Section
3.3).
3.3. Expression of oatp2 in Xenopus oocytes
In order to study the substrate selectivity of oatp2, uptake
experiments were performed (Table 1). As reported previ-
ously, oatp2 transports taurocholate, digoxin thyroid hor-
mones (T4, T3) and conjugated steroids (estradiol 17L-glucur-
onide and estrone sulfate), in a saturable manner [1,2]. As
shown in Table 1, the oatp2-expressing oocytes signi¢cantly
transported radiolabeled taurocholate, digoxin and thyroxine.
The oatp2-expressing oocytes also signi¢cantly transported
the conjugated steroid dehydroepiandrosterone sulfate
(DHEAS). In contrast, unconjugated steroids such as aldo-
sterone, estradiol and testosterone were not transported.
DHEAS is the most abundant product of the adrenal cortex
and provides a universal precursor of further androgenic and
estrogenic steroids in peripheral tissues. In the liver, DHEAS
is transported by a saturable carrier-mediated process in vivo
[8]. In the central nervous system (CNS), it has also been
shown that DHEAS is transported into the CNS, and in-
creases neural excitability [9], improves memory [10] and en-
hances the survival of neurons in culture [11]. Furthermore,
Kullak-Ublick et al. reported that human OATP is one of the
genes responsible for transporting DHEAS in the brain [12].
Therefore, oatp2 may be another candidate transporter which
is responsible for taking up DHEAS in the brain and liver.
In the brain, some peptides can enter the CNS through
both non-saturable and saturable transporting mechanisms
[13]. Our recent study in situ hybridization revealed that
oatp2 mRNA is widely expressed in the rat brain (especially
in the choroid plexus, hippocampus and cerebellum) [1]. Be-
cause oatp2 is also detected in the rat brain at the protein
level (Fig. 1), we studied whether oatp2 transports peptides.
Among the peptides tested, the N1 opioid receptor agonist
[D-Pen2,D-Pen5]enkephalin (DPDPE) was transported signi¢-
cantly more than the other opioid receptor agonists Leu-en-
kephalin, [D-Ala2,Glu4]deltorphin (a selective N2 agonist) and
D-Ala2,N-Me-Phe4,Gly5-ol (DAMGO, a selective W opioid re-
ceptor agonist) (Table 1). DPDPE is an enzymatically stable
N1 opioid receptor-selective peptide which produces analgesia
[14,15]. The passage of DPDPE across the blood-brain and
the blood-cerebrospinal £uid barriers has been well investi-
gated [16^19]. Thomas et al. further revealed a saturable
DPDPE uptake into the brain that followed Michaelis-Ment-
en kinetics [20]. In the liver, the existence is also suggested of a
facilitated transport system for DPDPE which may mediate
the rapid disappearance from the systemic circulation [21].
Thus, oatp2 appears to be one of the molecules that is in-
volved in the uptake of DPDPE in vivo.
Leu-enkephalin was weakly transported by the oatp2-ex-
pressing oocytes. Although carrier-mediated mechanisms for
Leu-enkephalin across the blood-brain barrier have been pre-
dicted [22], the uptake of DPDPE into the brain was not
inhibited by Leu-enkephalin [16] and [D-Ala2,Glu4]deltorphin
[15]. Because oatp2 transports both DPDPE and Leu-enkeph-
alin, the existence of additional candidate transporter(s) or
mechanisms for such peptides in the CNS is suggested.
In our experiment, oatp2 transported biotin signi¢cantly
(Table 1). Recently, a rat cDNA encoding a 12 transmem-
brane type transporter which transports biotin and pantothen-
ate in a Na-dependent manner has been isolated [23]. Thus,
the present results raise the possibility that multiple transport-
ing mechanisms would be responsible for the transport of
biotin.
So far, multispeci¢city of the oatp family substrate has been
reported [1,2,24]. Both rat oatp1 and human OATP transport
taurocholate, 17-L-estradiol glucuronide and estrone sulfate
with signi¢cant di¡erences in initial uptake rate and apparent
Km values [2,23,24]. In addition, no reports on human OATP-
or oatp1-mediated uptake of substrates described in this re-
port (i.e. thyroxine, DPDPE, Leu-enkephalin, biotin) have
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Table 1
Uptake of compounds by oatp2-expressing oocytes
Tracer (WM) Tracer uptake (pmol/oocyte) Uptake ratio (oatp2/H2O)
H2O oatp2
Thyroxine (1) 0.29 þ 0.01 3.8 þ 1.0 13 **
Taurocholate (12) 0.06 þ 0.02 3.89 þ 0.18 65 **
Estradiol 17L-glucuronide (0.76) 0.18 þ 0.01 0.60 þ 0.07 3.3 **
Estrone sulfate (0.76) 0.10 þ 0.02 0.97 þ 0.11 9.5 **
DHEAS (0.44) 0.027 þ 0.002 1.7 þ 0.14 61 **
Digoxin (2.7) 0.16 þ 0.11 4.2 þ 0.45 26 **
DPDPE (12) 0.018 þ 0.004 1.3 þ 0.3 72 **
Leu-enkephalin (1) 0.31 þ 0.02 0.43 þ 0.02 1.4 *
Biotin (0.69) 0.027 þ 0.001 0.045 þ 0.008 1.7 *
[D-Ala2,Glu4]Deltorphin (0.76) 0.12 þ 0.01 0.15 þ 0.02 1.3
DAMGO (0.76) 0.01 þ 0.001 0.013 þ 0.002 1.3
Aldosterone (0.48) 0.74 þ 0.02 0.76 þ 0.04 1.0
Estradiol (1) 6.2 þ 0.57 6.35 þ 0.45 1.0
Testosterone (0.40) 2.2 þ 0.1 2.06 þ 0.13 0.9
The uptake experiments were performed at the concentrations indicated. The oatp2/water uptake ratio (%) is shown. Values are means þ S.E.M. of
8^15 oocyte determinations. Signi¢cance between water-injected and oatp2-cRNA-injected oocytes was determined by unpaired t-test (*P6 0.05
and **P6 0.01).
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been made. Thus, further pharmacological characterization of
the substrate speci¢cities among the oatp family should pro-
vide new insight into bile acid formation and greater under-
standing of the multispeci¢city of the oatp family.
In conclusion, oatp2 is revealed to be expressed in the brain
and liver at the protein level. In the liver, oatp2 is located at
the basolateral membrane of the hepatocytes, suggesting the
facilitated transport of thyroid hormones, various organic
anions, conjugated steroids and neuropeptides.
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